Belimumab
Top View
- Chemotherapy Dose Rounding
- Emerging Therapies in Immune Thrombocytopenia
- Benlysta® (Belimumab) Prior Authorization With
- Ocrevus™ (Ocrelizumab)
- IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
- Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
- BENLYSTA Safely and Effectively
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- Benlysta® (Belimumab) - Effective May 1, 2018
- OCREVUS (Ocrelizumab) MB9941
- Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis (COVIDOSE)
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Australian Public Assessment Report for Belimumab
- Injection, for Intravenous Use. Benlysta (Belimumab)
- Systemic Lupus Erythematosus
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab